Program
PA-111
A development code.
Its studies are mostly in Dyslipidemias, led by Yuhan.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Yuhan | 22 open or running | phase 1since Apr 10, 2025 | Apr 10, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2025First study: phase 1 study in Mixed DyslipidemiaFirst studyNCT06932705 · 48 planned · Korea, Republic of
- May 9, 2025Phase 1 study in Mixed DyslipidemiaNCT06976489 · 40 planned · Korea, Republic of
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06976489Mixed Dyslipidemia · Korea, Republic of | 1 | Not yet recruiting | Jul 2025 | 40 |
| NCT06932705Mixed Dyslipidemia · Korea, Republic of | 1 | Recruiting | May 2025 | 48 |
How it is read
Names in the registry
- “PA-111”, 2 entries
Codes read as this program: PA111.
Conditions, from the studies’ own filings
- Dyslipidemias, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.